Form 4: Charles River Labs Exec Buys Shares

Glenn Coleman, EVP & Chief Financial Officer of Charles River Laboratories International, Inc., acquired 6,640 shares of common stock.

Summary

• Glenn Coleman, the Executive Vice President and Chief Financial Officer of Charles River Laboratories International, Inc., acquired 6,640 shares of common stock on May 29, 2026.
• The acquisition was made at a price of $180.71 per share.
• Following this transaction, Mr. Coleman beneficially owns 27,752 shares of common stock.
• The acquired shares are part of a transaction made pursuant to a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents an insider purchase under a pre-arranged plan, indicating a level of confidence without strong directional signals.

Positives

• Insider buying can signal confidence in the company's future prospects.
• The transaction was made under a Rule 10b5-1(c) plan, suggesting a pre-planned and potentially routine transaction rather than a reaction to immediate non-public information.

Future Outlook

The filing does not contain specific forward-looking statements or guidance. However, the acquisition of shares by a key executive under a 10b5-1 plan may imply a continued belief in the company's stability and growth.

Industry Context

StockSavvy.ai notes that insider transactions, particularly acquisitions by senior financial officers, are closely watched as potential indicators of management's view on the company's valuation and future performance within the contract research organization (CRO) and life sciences sector.

Stakeholder Impact

• Shareholders: May interpret the purchase as a positive signal of management's confidence in the company's stock value.
• Employees: May see this as a sign of stability and positive outlook from leadership.
• Creditors: Unlikely to be directly impacted by this specific transaction.

Key Dates

Keywords

Charles River Laboratories, CRL, Form 4, Insider Trading, Stock Acquisition, Glenn Coleman, CFO, Securities Exchange Act